SLSharon LewinAO, FRACP, PhD, FAHMSVideoHIVViral Hepatitis and Liver DiseaseAPACC 2016Towards an HIV Cure; understanding the major barriers | Sharon Lewin, AO, FRACP, PhD, FAHMSView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Management of DAA Failures | Gregory T. Everson, MDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Post-LT Renal Failure and HCV Rx | Peter Ferenci, MDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Obstacles to Treatment: Renal Disease, Ribavirin, DDIs | Michael Charlton, MDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016What Are the Treatment Options? | Maria Londoño, MDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Use of HCV+ Donor Grafts | Didier Samuel, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Achieving SVR in CTP C – MELD Purgatory | Christophe Duvoux, MDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016When to Treat HCV in a Waiting List Patient? | Stefano Fagiuoli, MDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016What Are the Treatment Options? | Xavier Forns, MDView Video
VideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Treatment Experienced GT3 patient with Cirrhosis | Geoffrey McCaughan, MD, PhDView Video
KAKosh AgarwalMDVideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Is Treatment Cost-effective? | Kosh Agarwal, MDView Video
NTNorah TerraultMD, MPH, FAASLDVideoViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Who Should We Treat? What is the “Point-of-No-Return”? | Norah Terrault, MD, MPH, FAASLDView Video
